{"organizations": [], "uuid": "bcee63e308e352d8bcc19fe30d9967487730c951", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180504.html", "section_title": "Archive News &amp; Video for Friday, 04 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-nicox-q1-net-revenue-at-0075-milli/brief-nicox-q1-net-revenue-at-0-075-million-euros-idUSFWN1SA1J7", "country": "US", "domain_rank": 408, "title": "BRIEF-Nicox Q1 Net Revenue At 0.075 Million Euros", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.166, "site_type": "news", "published": "2018-05-04T13:36:00.000+03:00", "replies_count": 0, "uuid": "bcee63e308e352d8bcc19fe30d9967487730c951"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-nicox-q1-net-revenue-at-0075-milli/brief-nicox-q1-net-revenue-at-0-075-million-euros-idUSFWN1SA1J7", "ord_in_thread": 0, "title": "BRIEF-Nicox Q1 Net Revenue At 0.075 Million Euros", "locations": [], "entities": {"persons": [{"name": "nicox", "sentiment": "negative"}], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 4 (Reuters) - NICOX SA:\n* AS OF MARCH 31, 2018, THE GROUP HAD CASH AND CASH EQUIVALENTS OF €36.3 MILLION AS COMPARED WITH €41.4 MILLION AT DECEMBER 31, 2017\n* ZERVIATE EXPECTED TO BE LAUNCHED IN U.S. BY EYEVANCE PHARMACEUTICALS FOR THE 2018 FALL ALLERGY SEASON\n* NET REVENUE FOR THE FIRST QUARTER OF 2018 WAS €0.075 MILLION\n* NCX 470 U.S. INVESTIGATIONAL NEW DRUG (IND) SUBMISSION ENABLING PHASE 2 CLINICAL STUDY IN GLAUCOMA PATIENTS PLANNED IN Q3 2018.\n* NCX 4251 U.S. IND SUBMISSION ENABLING PHASE 2 CLINICAL STUDY IN BLEPHARITIS PATIENTS PLANNED IN Q1 2019 Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-04T13:36:00.000+03:00", "crawled": "2018-05-05T12:08:50.010+03:00", "highlightTitle": ""}